Evaluation of efficacy and safety of daily versus alternate day dapagliflozin therapy among patients with type 2 diabetes mellitus: An open label randomized controlled study - DAPA-ADT

Department of Science Technology Renewable Energy Chandigarh Administration Chandigarh0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

试验速览

暂无简介。

•1. Male and female patients with T2DM visiting the General Medicine/Endocrinology OPD/Ward who are taking stable dose of metformin more than or equal to 1500 mg per day therapy for a duration 3 months or more.
•2.Age 18-59 years
•3.Glycosylated hemoglobin (HbA1c) values between 7-9%

•- Subjects with type 1 DM
•-Patients who have taken metformin treatment for a duration of less than 3 months
•-Patients taking add on anti-diabetic drugs over and above metformin
•-Patients having allergy to any of the study drugs
•-Pregnant and lactating women
•-Patients with kidney dysfunction (serum
•creatinine level more than 1.5 times more than the upper limit of normal range)
•- Patients with hepatic dysfunction (alanine aminotransferase and/or aspartate aminotransferase levels 3-fold more than the upper limit of normal range)
•-Patients having acute infections, recent trauma or surgery for which the treatment is ongoing and patients have not yet recovered
•-Patients with history of recent diabetic ketoacidosis
•-Patients with history of active cancer or past history of cancer
•-Patients with past history of family history of urinary bladder cancer
•-Patients presenting with hematuria or symptoms and signs suggestive of bladder cancer
•-Patients who are not able or willing to give a written informed consent.

发起方

Department of Science Technology Renewable Energy Chandigarh Administration Chandigarh